Sickle Cell Anemia - A Drug Pipeline Analysis Report by Technavio

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest drug pipeline analysis report on sickle cell anemia. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of sickle cell anemia. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005984/en/

Technavio has published a new report on the drug development pipeline for the treatment of sickle cell anemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

Sickle cell anemia: An overview

Sickle cell anemia is a disease caused by the production of abnormal hemoglobin. It binds with other abnormal hemoglobin molecules within the red blood cells and leads to rigid deformation of the cell. This deformation inhibits the ability of the cell to pass through small vascular channels, which may result in sludging and congestion of vascular beds, followed by tissue ischemia and infarction. Infarction is common throughout the body in a patient with sickle cell anemia and is responsible for the earliest clinical manifestation and acute pain crisis.

Tropical regions such as sub-Saharan Africa, tribal regions of India, and the Middle East, have the highest frequency of sickle cell anemia. About 75% of the total cases of sickle-cell diseases occur in Africa. Various studies conducted by the WHO have shown that 2% of the newborns in Nigeria have sickle cell anemia.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Sickle cell anemia: Segmentation of pipeline molecules

Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with more than 48% of the pipeline molecules administered through this mode.

Between companies and institutions, institutions led the drug development space for the treatment of sickle cell anemia. Some of the key players include ApoPharma, ArQule, AstraZeneca, bluebird bio, and Imara.

Looking for more information? Request your free sample today

Some of the key topics covered in the report include:

1. Scope of the Report

2. Regulatory Framework

3. Drug Development Landscape

• Drugs under development

4. Drug Development Strategies

• Therapies employed
• Route of administration
• Therapeutic modality
• Mechanism of action

5. Recruitment Strategies

• Geographical coverage
• Recruitment status
• Gender
• Age

6. Key Companies

• Type of players
• Company overview

7. Discontinued and Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005984/en/